Profile of aclidinium bromide in the treatment of chronic obstructive pulmonary disease

Michael W. Sims, Reynold A. Panettieri

Research output: Contribution to journalArticlepeer-review

16 Scopus citations


Bronchodilators provide the mainstay of pharmacologic therapy for chronic obstructive pulmonary disease (COPD), and anticholinergic bronchodilators, in particular, appear to be the most effective. There are currently two anticholinergic agents available in the US for the treatment of COPD (ipratropium bromide and tiotropium bromide), but several others are in various stages of development. Aclidinium bromide, a novel, long-acting, anticholinergic bronchodilator, is currently in Phase III trials for the management of COPD. Available evidence suggests that aclidinium is a safe and well tolerated drug with a relatively rapid onset and a suffcient duration of action to provide once-daily dosing. This article will provide a pharma-cologic Profile of aclidinium bromide and review the preclinical and clinical studies evaluating its safety and effcacy in the treatment of COPD.

Original languageEnglish (US)
Pages (from-to)457-466
Number of pages10
JournalInternational Journal of COPD
Issue number1
StatePublished - 2011
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine
  • Health Policy
  • Public Health, Environmental and Occupational Health


  • Aclidinium bromide
  • Bronchodilators
  • Chronic obstructive
  • Muscarinic antagonists
  • Pharmacokinetics
  • Pharmacology
  • Pulmonary disease


Dive into the research topics of 'Profile of aclidinium bromide in the treatment of chronic obstructive pulmonary disease'. Together they form a unique fingerprint.

Cite this